Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720692 · ClinicalTrials.gov registry record · Phase 3
Evaluation of N1539 Following Major Surgery
A Phase 3 study, sponsored by Baudax Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 722
- Enrollment target
NCT02720692: Completed Phase 3 study, sponsored by Baudax Bio.
NCT02720692 is a Phase 3 study that has completed, run by Baudax Bio. The registered enrollment target is 722 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02720692, a Phase 3 study, has completed, sponsored by Baudax Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 722 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of N1539 in a variety of post-surgical conditions.
Primary Outcome
Number of subjects reporting 1 or more treatment-emergent adverse events
Interventions
- DRUG Intravenous Placebo
- DRUG N1539
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 722 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-05 |
| Phase | Phase 3 |
What the finished NCT02720692 record still lists
NCT02720692 is an interventional study that assigns participants to a tested intervention. The registered 722 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Intravenous Placebo is the first listed.
NCT02720692 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02720692 about?
NCT02720692 is a clinical study titled "Evaluation of N1539 Following Major Surgery". The primary objective of this study is to evaluate the safety and tolerability of N1539 in a variety of post-surgical conditions.
What is the current status of trial NCT02720692?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 722 participants. The study started on 2016-03. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02720692?
The interventions under investigation include: Intravenous Placebo (DRUG), N1539 (DRUG).
Who is sponsoring clinical trial NCT02720692?
This trial is sponsored by Baudax Bio, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02720692's enrollment target sits among peer trials
722 494th of 2000 higher than 1,507 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06116149 · 722 participants · NA
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- NCT07088068 · 723 participants · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia